Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Langner, S; Staber, PB; Schub, N; Gramatzki, M; Grothe, W; Behre, G; Rabitsch, W; Urban, C; Linkesch, W; Neumeister, P.
Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Bone Marrow Transplant. 2008; 42(4): 275-279.
Doi: 10.1038/bmt.2008.157
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Langner Stefan
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Neumeister Peter
- Staber Philipp
- Urban Ernst-Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In this multicenter study, 30 patients undergoing matched related or unrelated allogeneic stem-cell transplantation for leukemia were treated with palifermin, and retrospectively compared to a matched control group. Palifermin recipients transplanted with an unrelated donor showed a significant reduction of severity, incidence and duration of oral mucositis WHO grades 2-4. In addition, in the palifermin group the use of opioid analgesics and the duration of total parenteral nutrition decreased, whether stem cells were used from matched related or unrelated donors. No beneficial influence of palifermin on the incidence and severity of acute GVHD (aGVHD) was apparent. The incidence and duration of febrile neutropenia, documented infections, hematopoietic recovery or overall survival remained unchanged. The most common adverse effects included rash or erythema, generally mild and transient in appearance. Thus, the administration of palifermin was generally well tolerated and safe, and significantly reduced oral mucositis whereas--regardless of donor status--no effect on the incidence and severity of aGVHD was seen.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Female -
- Fibroblast Growth Factor 7 - adverse effects Fibroblast Growth Factor 7 - therapeutic use
- Graft vs Host Disease - prevention and control
- Hematopoietic Stem Cell Transplantation - methods
- Humans -
- Leukemia - therapy
- Male -
- Middle Aged -
- Retrospective Studies -
- Stomatitis - prevention and control
- Transplantation Conditioning -
- Transplantation, Homologous -
- Find related publications in this database (Keywords)
- palifermin
- matched related and unrelated allogeneic hematopoietic stem-cell transplantation
- acute GVHD